Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and ADA guidelines surrounding a multi-level approach for diabetes complication reduction. They also discuss the latest advances in insulin therapy and the latest clinical trials on cardiovascular effects of glucose-lowering agents, and advances in glucagon use for the treatment of hypoglycaemia.
The abstract entitled: ‘New Horizons in T2D Management and Cardiorenal Risk Reduction: A Pharmacotherapeutic Update‘ was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.
Questions:
- What factors increase cardiorenal risks in patients with type 2 diabetes (T2D)? (0:25)
- What have been the latest advances in insulin therapy? (1:20)
- Could you give us a brief overview of the latest clinical trials on cardiovascular effects of glucose-lowering agents? (3:47)
- How have the guidelines been updated to reflect these recent findings? (5:31)
- Can you tell us a little about the latest advances in glucagon use for the treatment of hypoglycaemia? (6:30)
Disclosures:
Clipper Young was a consultant for Sanofi (October 2021); and has received grant support from Sutter Health.
Shirley Wong has nothing to disclose in relation to this video interview.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ADCES 2022
Click here for more related content.
